Table 2 |
||||
Change in IOP (mmHg) from baseline to week 4 (worse eye, ANCOVA, PP population) | ||||
Latanoprost concentration (μg/mL) | ||||
50 | 75 | 100 | 125 | |
N | 69 | 66 | 71 | 68 |
8 a.m. IOP | ||||
LS mean change (mmHg)* | −10.13 | −9.59 | −10.02 | −9.06 |
Adjusted difference in LS mean ± SEM^{†} | 0.54 ± 0.46 | 0.12 ± 0.45 | 1.07 ± 0.45 | |
(90% CI) | (−0.22, 1.29) | (−0.63, 0.86) | (0.32, 1.82) | |
p-value^{‡} | 0.879 | 0.602 | 0.990 | |
4 p.m. IOP | ||||
LS mean change (mmHg)* | −8.90 | −8.29 | −8.81 | −8.34 |
Adjusted difference in LS mean ± SEM^{†} | 0.60 ± 0.47 | 0.09 ± 0.45 | 0.55 ± 0.46 | |
(90% CI) | (−0.16, 1.37) | (−0.67, 0.84) | (−0.20, 1.31) | |
p-value^{‡} | 0.902 | 0.575 | 0.885 |
ANCOVA analysis of covariance, CI confidence interval, IOP intraocular pressure, LS least square, PP per protocol, SEM standard error of the mean.
*Adjusting for baseline IOP (covariate) with dose group and center as factors.
^{†}Higher concentration minus latanoprost 50 μg/mL; a negative difference in LS mean indicates that the higher concentration has a greater effect than latanoprost 50 μg/mL.
^{‡}One-sided p-value.
Eveleth et al.
Eveleth et al. BMC Ophthalmology 2012 12:9 doi:10.1186/1471-2415-12-9